[Cutaneous and soft skin infections due to non-tuberculous mycobacteria].
The frequency of isolation as well as the number of species of non-tuberculous mycobacteria (NTM) has increased in the last years. Nearly every pathogenic species of NTM may cause skin and soft tissue infections, but rapidly growing mycobacteria (Mycobacterium fortuitum, Mycobacterium chelonae and Mycobacterium abscessus), Mycobacterium marinum and Mycobacterium ulcerans are the most commonly involved. Many of these cutaneous mycobacteriosis, such as rapidly growing mycobacteria, M. marinum, Mycobacterium avium complex, Mycobacterium kansasii or Mycobacterium xenopi are world-wide distributed. In contrast, some others have a specific geographical distribution. This is the case of M. ulcerans, which causes a cutaneous diseases endemic of Central and West Africa (Buruli ulcer) and Australia (Bairnsdale ulcer), being the third mycobacterial infection after tuberculosis and leprosy. Cutaneous mycobacteriosis usually appear either after contact of traumatic or surgical wounds with water or other contaminated products, or, secondarily, as a consequence of a disseminated mycobacterial disease, especially among immunosuppressed patients. For an early diagnosis, it is necessary to maintain a high degree of suspicion in patients with chronic cutaneous diseases and a history of trauma, risk exposure and negative results of conventional microbiological studies. In general, individualized susceptibility testing is not recommended for most NTM infections, except for some species, and in case of therapeutic failure. Treatment includes a combination of different antimicrobial agents, but it must be taken into account that NTM are resistant to conventional antituberculous drugs. Severe cases or those with deep tissues involvement could also be tributary of surgical resection.
Alcaide
Fernando
F
IDIBELL-Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España. falcaide@bellvitgehospital.cat <falcaide@bellvitgehospital.cat>
Esteban
Jaime
J
D000350:Africa, Central / Q000453:epidemiology; D000354:Africa, Western / Q000453:epidemiology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001315:Australia / Q000453:epidemiology; D054312:Buruli Ulcer / Q000453:epidemiology; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D016867:Immunocompromised Host; D009165:Mycobacterium Infections, Nontuberculous / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D019910:Mycobacterium marinum / Q000302:isolation & purification / Q000472:pathogenicity; D019911:Mycobacterium ulcerans / Q000302:isolation & purification / Q000472:pathogenicity; D009170:Nontuberculous Mycobacteria / Q000302:isolation & purification / Q000472:pathogenicity; D009894:Opportunistic Infections / Q000453:epidemiology / Q000382:microbiology; D017192:Skin Diseases, Bacterial / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D018461:Soft Tissue Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D012988:Soil Microbiology; D014871:Water Microbiology; D014946:Wound Infection / Q000382:microbiology
D000900:Anti-Bacterial Agents